Back to News
Market Impact: 0.25
Imvax Announces Additional Data from Phase 2b Clinical Trial of IGV-001 in Newly Diagnosed GBM and Provides Update on Planned Clinical Development
Source: Business Wire
Healthcare & Biotech
Imvax announced Phase 2b trial results for IGV-001 in 99 patients with newly diagnosed glioblastoma and provided an update on its clinical development program. The release headline does not disclose efficacy, safety, or statistical outcomes, limiting assessment of the trial's investment significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- A sharp stock market decline could lie around the corner, Wells Fargo warns
- Why is Vera Therapeutics stock reversing its premarket gains?
- H.C. Wainwright raises Scholar Rock stock price target on FDA approval